Bristol-Myers Squibb Company (BMY) Stock Analysis
Breakout setup
Healthcare · Drug Manufacturers - General
Sell if holding. Multiple concerning factors at $58.33: Leverage penalty (D/E 2.3): -1.5; Concentration risk — Geographic: United States (69.0%).
Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology, cardiovascular, and neuroscience, generating $48.2B in total 2025 revenues. The US accounts for 69% of revenues with key products including Eliquis, Opdivo,... Read more
Sell if holding. Multiple concerning factors at $58.33: Leverage penalty (D/E 2.3): -1.5; Concentration risk — Geographic: United States (69.0%). Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Score 6.2/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on news legal. Suitability: conservative.
Recent Developments — Bristol-Myers Squibb Company
Latest news
- Do Wall Street Analysts Like Bristol-Myers Squibb Stock? - Yahoo Finance — Yahoo Finance neutral
- Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow - StockStory — StockStory neutral
- Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts - Yahoo Finance — Yahoo Finance positive
- Bristol-Myers Squibb: Vestmo Stock of the Week - Barron's — Barron's positive
- Cantor Fitzgerald raises Bristol-Myers Squibb stock price target to $54 - Investing.com — Investing.com positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicUnited States69%10-K Item 1: 'United States| 69 | %'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $58.33: Leverage penalty (D/E 2.3): -1.5; Concentration risk — Geographic: United States (69.0%). Chart setup: Golden cross, above all MAs, RSI 53, MACD bullish. Prior stop was $55.49. Score 6.2/10, moderate confidence.
Take-profit target: $59.56 (+2.1% upside). Prior stop was $55.49. Stop-loss: $55.49.
Concentration risk — Geographic: United States (69.0%); Leverage penalty (D/E 2.3): -1.5; Consecutive earnings misses (2).
Bristol-Myers Squibb Company trades at a P/E of 16.1 (forward 9.3). TrendMatrix value score: 8.8/10. Verdict: Sell.
36 analysts cover BMY with a consensus score of 3.5/5.
What does Bristol-Myers Squibb Company do?Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology,...
Bristol-Myers Squibb discovers, develops, and markets innovative medicines across oncology, hematology, immunology, cardiovascular, and neuroscience, generating $48.2B in total 2025 revenues. The US accounts for 69% of revenues with key products including Eliquis, Opdivo, Revlimid, and growth portfolio drugs. Multiple products face patent expiry pressures and the IRA's maximum fair price for Eliquis took effect January 1, 2026.